Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults

NCT02239172 is registered in ClinicalTrials.gov with Fraunhofer, Center for Molecular Biotechnology as lead sponsor.

NCT NCT02239172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02239172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
May 31, 2015
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax